Latest Biotech News

Abbott reported that Diagnostics revenue rose 6% year over year to $2.18 billion in Q1 2026, marking the first quarter of results after completion of its Exact Sciences acquisition. Core...

New FDA documents show Eli Lilly has been asked to evaluate liver and cardiovascular risks for its recently approved obesity pill Foundayo as part of ongoing trials, following approval conditions....

Revolution Medicines priced a large concurrent offering—its follow-on stock and debt raise totaling $2 billion—just days after topline Phase 3 results for daraxonrasib in metastatic pancreatic...

Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million to expand its oncology antibody-drug conjugate pipeline, betting on dual-payload delivery to improve tumor killing and...

The FDA released draft guidance outlining how sponsors should use next-generation sequencing and bioinformatics in nonclinical studies to assess safety risks for genome-edited human gene...

Roche said it will run another Phase 3 trial of Duchenne muscular dystrophy gene therapy Elevidys aimed at supporting European approval after the European regulators issued a negative review last...

Travere Therapeutics’ Filspari (sparsentan) cleared a key regulatory milestone by becoming the first fully FDA-approved treatment for focal segmental glomerulosclerosis (FSGS). The expanded label...

Bain Capital backed Beeline Medicines emerged from stealth with a $300 million Series A and five immunology programs licensed from Bristol Myers Squibb. The startup’s pipeline includes afimetoran,...

Tempus announced it will distribute Predicta Biosciences’ whole-genome sequencing-based GenoPredicta assay for multiple myeloma, bringing the test into Tempus’ diagnostic ecosystem. GenoPredicta...

Terremoto Biosciences raised $108 million in a Series C financing to advance small-molecule drugs targeting AKT, with the company describing its covalency technology approach to improve efficacy...

Revolution Medicines priced a $1.5 billion follow-on offering, following top-line Phase 3 results for its RAS inhibitor daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The transaction...

The FDA released draft guidance focused on using next-generation sequencing and bioinformatics to evaluate safety for genome-edited gene therapy products. The document centers on nonclinical...

Cabaletta Bio’s investigational CD19 CAR T therapy, rese-cel (resecabtagene autoleucel), was manufactured on Cellares’ automated Cell Shuttle system and infused into the first two patients....

AWS launched Amazon Bio Discovery, an agentic AI platform designed to speed antibody discovery by combining a catalog of foundation models with an AI agent that selects models and evaluates...

In a prospective multicenter evaluation, researchers used genomics-guided off-label precision therapies under the Dutch Drug Rediscovery Protocol (DRUP) to identify molecular subgroups with...

Bain Capital seeded a new immunology platform that launched out of stealth as Beeline Medicines, built around five shelved Bristol Myers Squibb assets. The company surfaced with a Series A of $300...

Tempus secured a distribution agreement to roll out Predicta Biosciences’ GenoPredicta whole-genome sequencing assay for multiple myeloma. The lab-developed test is designed to identify high-risk...

Travere Therapeutics’ Filspari (sparsentan) gained full FDA approval for focal segmental glomerulosclerosis (FSGS), expanding its rare kidney disease label after earlier approvals in IgA...

Regeneron entered radiopharmaceutical development via a partnership with Telix Pharmaceuticals, a deal valued at up to $4.3 billion. The companies plan to co-develop and co-commercialize precision...

Obsidian Therapeutics moved toward public-market access through a reverse merger with Galera Therapeutics, with plans to trade on the Nasdaq under ticker OBX. The combined company also secured...